ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This study suggests a novel role of cellular differentiation status and CD38 expression on acquisition of BCR-ABL mutations, and the potential therapeutic use of ATRA to inhibit CML acquired resistance to tyrosine kinase inhibitors.